Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/CIMA-AEMPS/LOPERAMIDA AUROVITAS 2 MG CAPSULAS DURAS

Approved

STANDARD

LOPERAMIDA AUROVITAS 2 MG CAPSULAS DURAS

Aurovitas Spain, S.A.U.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Jul 21, 2022
Approval ID: 6952833e4aaf26cf
Company: Aurovitas Spain, S.A.U.
Type: Standard

Approval Details

Approval Id: 6952833e4aaf26cf
Drug Cima Aemps Name: LOPERAMIDA AUROVITAS 2 MG CAPSULAS DURAS
Register Number: 87970
Holder Company Name: Aurovitas Spain, S.A.U.
Marketing Company Name: Aurovitas Spain, S.A.U.
Authorization Date: 2022-07-21
Dosage Form: CÁPSULA DURA
Dose: 2 mg
Route Of Administration: VÍA ORAL
Prescription Type: Sin Receta
Commercialized: Yes
Company Name: Aurovitas Spain, S.A.U.

Active Ingredients

LOPERAMIDA HIDROCLORURO

2 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Jul 21, 2022

Approval ID

6952833e4aaf26cf

Type

Standard

Back to CIMA-AEMPS Approvals

LOPERAMIDA AUROVITAS 2 MG CAPSULAS DURAS - CIMA-AEMPS Drug Approval Details